Climb Bio (CLYM) Change in Account Payables (2020 - 2026)
Climb Bio (CLYM) reported Change in Account Payables of -$1.4 million for Q1 2026, down 2056.94% on a YoY basis from $72000.0 in Q1 2025, and down 178.63% quarter-over-quarter from $1.8 million in Q4 2025.
Climb Bio (CLYM) Change in Account Payables (2020 - 2026) Analysis & Trends
Climb Bio has reported Change in Account Payables for 7 years, with the latest figure at -$1.4 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 2056.94% year-over-year to -$1.4 million; the trailing twelve-month figure through Mar 2026 stood at $83000.0 (up 109.11% YoY), and the FY2025 full-year result was $1.6 million, up 262.41% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$1.4 million, down from $1.8 million in the prior quarter.
- The five-year high for Change in Account Payables was $1.8 million in Q4 2025, with the low at -$1.4 million in Q1 2026.
- Historically, Change in Account Payables has averaged -$126294.1 across 5 years, with a median of $14000.0 in 2023.
- Annual changes were most pronounced in 2022 — Change in Account Payables surged 608.7% — and 2024, when it tumbled 8528.57%.
- Climb Bio's Change in Account Payables stood at -$744000.0 in 2022, then increased by 9.68% to -$672000.0 in 2023, then jumped by 161.61% to $414000.0 in 2024, then surged by 332.85% to $1.8 million in 2025, then tumbled by 178.63% to -$1.4 million in 2026.
- The last three Change in Account Payables figures came in at -$1.4 million (Q1 2026), $1.8 million (Q4 2025), and -$393000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -9.42 Mn |
| 10 | Climb Bio | 740.73 Mn | 740.73 Mn | - | -1.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.41 Mn |
| Mar 31, 2026 | -1.41 Mn |
| Dec 31, 2025 | 1.79 Mn |
| Dec 31, 2025 | 1.79 Mn |
| Sep 30, 2025 | -393,000.00 |
| Sep 30, 2025 | -393,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Jun 30, 2025 | 93,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Dec 31, 2024 | 414,000.00 |
| Dec 31, 2024 | 414,000.00 |
| Sep 30, 2024 | -217,000.00 |
| Sep 30, 2024 | -217,000.00 |
| Jun 30, 2024 | -1.18 Mn |
| Jun 30, 2024 | -1.18 Mn |
| Mar 31, 2024 | 20,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | -672,000.00 |
| Dec 31, 2023 | -672,000.00 |